Al. Foo et al., THE EFFECT OF NEDOCROMIL SODIUM ON HISTAMINE RESPONSIVENESS IN CLINICALLY STABLE ASTHMATIC-CHILDREN, The Journal of asthma, 30(5), 1993, pp. 381-390
A double-blind, randomized, placebo-controlled, parallel-group study w
as undertaken in 120 clinically stable asthmatic children (aged 6-19 y
ears) to determine the ability of 8 weeks of treatment with nedocromil
sodium (4 mg, three times a day) to reduce the level of histamine res
ponsiveness. Despite the subjects being clinically stable and reportin
g few asthma symptoms, approximately one-third had abnormal pulmonary
function on enrollment into the study. Statistically significant incre
ases in pulmonary function were seen in the group treated with nedocro
mil sodium but not in the control group (p = 0.01). Furthermore, 52% o
f the individuals with abnormal pulmonary function returned to normal
following treatment with nedocromil sodium compared to 11% of those wi
th abnormal pulmonary function who received placebo. However, there we
re no differences in the level of histamine responsiveness between the
two treatment groups at baseline or after 4 or 8 weeks of treatment w
ith nedocromil sodium or placebo. These data suggest that the level of
histamine responsiveness is not intimately related to the level of as
thma control in children.